Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2017 Oct;23(10):1729-1735. doi: 10.1016/j.bbmt.2017.06.022. Epub 2017 Jul 4.

Umbilical Cord Blood Cytomegalovirus Serostatus Does Not Have an Impact on Outcomes of Umbilical Cord Blood Transplantation for Acute Leukemia.

Author information

1
Anthony Nolan Research Institute, London, UK; Cancer Institute, University College London, London, UK. Electronic address: olganmd@gmail.com.
2
Department of Haematology, Churchill Hospital, University of Oxford, Oxford, UK; Eurocord, Hopital Saint Louis, Paris, France; Centre Scientifique de Monaco, Principality of Monaco; Servico de Hematologia, Hemoterapia e Terapia Celular, Hospital das Clinicas, Faculdale de Medicina da Universidade, Saṍ Paolo, Brazil.
3
Anthony Nolan Research Institute, London, UK; Department of Haematology, Churchill Hospital, University of Oxford, Oxford, UK.
4
Eurocord, Hopital Saint Louis, Paris, France; Service h'hematologie et therapie cellularie, Hopital Saint Antoine, Paris, France.
5
Eurocord, Hopital Saint Louis, Paris, France; Centre Scientifique de Monaco, Principality of Monaco.
6
NetCord Foundation and Liege Cord Blood Bank, University of Liege, Liege, Belgium.
7
Banc de Sang, Teixits, Barcelona, Spain.
8
Dusseldorf Cord Blood Bank, University of Dusseldorf, Dusseldorf, Germany.
9
Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Unité de Thérapie Cellulaire, Paris, France.
10
Centre of Transfusion Medicine, Cellular Therapy and Cryobiology, Milan, Italy.
11
NHS Cord Blood Bank, NHS Blood and Transplant, London, UK.
12
Besançon Cord Blood Bank of the Etablissement Français du Sang, Besançon, France.
13
Imperial College London, London, UK.
14
Anthony Nolan Research Institute, London, UK; Cancer Institute, University College London, London, UK.

Abstract

Several studies have reported an impact of adult hematopoietic stem cell donor cytomegalovirus (CMV) serostatus on allogeneic hematopoietic cell transplantation outcomes. Limited data, however, are available on the impact of cord blood unit (CBU) CMV serostatus on allogeneic umbilical cord blood transplantation (UCBT) outcomes. We analyzed, retrospectively, the impact of CBU CMV serostatus on relapse incidence (RI) and 2-year nonrelapse mortality (NRM) of single-unit CBU transplantation for acute leukemia. Data from 1177 de novo acute leukemia pediatric and adult patients transplanted within European Group for Blood and Marrow Transplantation centers between 2000 and 2012 were analyzed. CBUs were provided by the European Cord Blood Banks. The median follow-up time for live patients was 59.9 months. The recipients of CMV-seropositive and -seronegative CBUs showed a comparable RI (33% versus 35%, respectively, P = .6) and 2-year cumulative incidence of NRM (31% versus 32%, respectively, P = .5). We conclude that CBU CMV serostatus did not influence RI and NRM in de novo acute leukemia patients after allo-UCBT and should not be included as a criteria for cord blood choice.

KEYWORDS:

Acute leukemia; Cytomegalovirus; Umbilical cord blood transplantation

PMID:
28687394
DOI:
10.1016/j.bbmt.2017.06.022
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center